STOK vs TARS Stock Comparison
TARS currently leads STOK in this stock comparison, with AIQ scores of 65 vs 42. The clearest difference is value.
What is the main difference between STOK and TARS?
TARS leads the current stock comparison as Tarsus Pharmaceuticals, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Stoke Therapeutics, Inc. vs Tarsus Pharmaceuticals, Inc.
TARS leads
TARS leads by 23 AIQ points, primarily on Value and Momentum, but the lead has narrowed from 34 points over 30 sessions. Wall Street currently favors STOK on target upside.
Fragile: 3 of 6 evidence groups support TARS, its lead is narrowing, and its current signal state is conflicted.
Stoke Therapeutics, Inc.
Tarsus Pharmaceuticals, Inc.
The Algovestiq AIQ Score currently favors TARS over STOK, 65 versus 42 as of Nov 15, 2026. TARS's advantage is driven primarily by stronger value and momentum. TARS also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors STOK. 3 of 6 covered evidence groups favor TARS today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. TARS lead: Weakening — the AIQ differential moved from 34 to 23 points over 30 sessions.
Compare Stoke Therapeutics, Inc. and Tarsus Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare STOK and TARS against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value22 vs 75TARS +53
- Momentum47 vs 76TARS +29
- Quality42 vs 50TARS +8
- Risk Resilience59 vs 59Even
3 of 6 evidence groups favor TARS. TARS’s edge is concentrated in value and momentum.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum +1, not enough on its own to move the overall score.
New signals
- Price Reclaimed 50-Day MA — bullish, trend, medium horizon
- RSI Midline Reclaim — bullish, momentum, short horizon
Largest factor move: Value +2
New signals
- BB Upper Band Breach — bearish, volatility, short horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
TARS's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — STOK and TARS both carry a full feed there.
The central trade-off
TARS (Tarsus Pharmaceuticals, Inc.): the stronger current systematic profile, led by value and momentum.
STOK (Stoke Therapeutics, Inc.): the counter-case, on fundamentals, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
TARSTARS on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
STOKSTOK on combined revenue and EPS growth.
Value
TARSTARS on the peer-relative Value factor, by 53 points.
Momentum
TARSTARS on the Momentum factor, by 29 points.
Lower downside
TARSTARS carries the lower 1-month annualized volatility.
Analyst upside
STOKSTOK on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors TARS, analyst targets favor STOK. That disagreement is the most useful thing on this page.
| Measure | STOK | TARS | Note |
|---|---|---|---|
| Implied upside to target | +61.2% | +36.1% | STOK has more room |
| Target dispersion | 0% | +10.1% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 14 | 10 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor TARS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | TARS | 42 vs 65 |
| Fundamentals | STOKon balance | revenue growth 20.7% vs 11.9%; EPS growth -16.1% vs -32.5%; TTM ROE -20.9% vs -6.4%; gross margin 88.5% vs 93.2%; operating margin -9.1% vs -102% — STOK takes 3 of 5 decided legs, not all of them |
| Valuation | TARS | Value 22 vs 75 |
| Technicals | TARS | Price vs 50-day 0.9% vs 7.3%; vs 200-day -13.3% vs 18.1% |
| Risk Resilience | Even | Risk Resilience 59 vs 59 |
| Analyst expectations | STOK | Target upside 61.2% vs 36.1% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of STOK and TARS and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is wide at 23 points. (supports the conclusion holding)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on TARS.
How the comparison changed
120 daily snapshots · May 27 – Nov 13TARS lead: Weakening — the AIQ differential moved from 34 to 23 points over 30 sessions.
- Today
- TARS +23
- 42 vs 65
- 7 sessions ago
- TARS +26
- 40 vs 66
- 30 sessions ago
- TARS +34
- 36 vs 70
- 90 sessions ago
- TARS +22
- 44 vs 66
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 2 bearish / 2 neutral, conflicted
Only STOK
- Death Cross Active — bearish, trend, long horizon (16.39%)
- ADX Trend Weakening — neutral, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.31x)
- Price Reclaimed 50-Day MA — bullish, trend, medium horizon
- RSI Midline Reclaim — bullish, momentum, short horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
5 bullish / 1 bearish / 1 neutral, conflicted
Only TARS
- Golden Cross Active — bullish, trend, long horizon (10.12%)
- BB Upper Band Breach — bearish, volatility, short horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.
TARS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.83%, AIQ 0 points).
Price and the AIQ Score both moved up over the latest session (price +4.41%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1STOK closes the Value gap — currently 53 points behind, the largest single contributor to TARS's edge.
- 2STOK's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3TARS's conflicting signal state resolves bearish — it currently carries 5 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 11 points over 30 sessions, and a further 23-point move would eliminate TARS's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
STOK leads on balance| Metric | STOK | TARS |
|---|---|---|
| Revenue growth (YoY) | 20.7% | 11.9% |
| EPS growth (YoY) | -16.1% | -32.5% |
| Gross margin | 88.5% | 93.2% |
| Operating margin | -9.1% | -102% |
| Return on equity (TTM) | -20.9% | -6.4% |
| Debt to equity | 0 | 0.85 |
Performance
TARS leads 6 of 6 windows| Metric | STOK | TARS |
|---|---|---|
| 1 week (5 sessions) | 0.5% | 17% |
| 1 month (20 sessions) | 10.4% | 17.9% |
| 3 months (63 sessions) | -17% | 13.7% |
| 6 months (126 sessions) | -11.3% | 28.5% |
| Year to date | -15.9% | -2% |
| 1 year (252 sessions) | 6.2% | 7.3% |
Technicals
TARS has the stronger structure| Metric | STOK | TARS |
|---|---|---|
| RSI (14) | 51.3 | 64.8 |
| ADX (14) | 17.3 | 16.7 |
| Price vs 50-day | 0.9% | 7.3% |
| Price vs 200-day | -13.3% | 18.1% |
| Volatility (1M, annualized) | 48.9% | 44.7% |
Risk
Split| Metric | STOK | TARS |
|---|---|---|
| Beta | 0.96 | 0.56 |
| Sharpe ratio | 0.23 | 0.36 |
| Sortino ratio | 0.35 | 0.55 |
| Max drawdown | -41.3% | -32% |
| Current drawdown | -30.4% | -11.6% |
| Annualized volatility | 53.2% | 45% |
| Value at risk (95%) | -5% | -4.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, STOK or TARS?
On the Algovestiq AIQ Score, TARS is the stronger of the two as of Nov 15, 2026, scoring 65 against STOK's 42. The edge comes from value and momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is STOK or TARS the better buy right now?
TARS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor TARS over STOK?
The composite weights Quality, Value, Momentum and Risk Resilience. TARS leads Value by 53 points; TARS leads Momentum by 29 points; TARS leads Quality by 8 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, STOK or TARS?
Analyst price targets imply +61.2% upside for STOK and +36.1% for TARS, so the Street currently favors STOK. That points the opposite way to the AIQ Score, which favors TARS. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, STOK or TARS?
TARS is the better-valued of the two on the peer-relative Value factor. TARS on the peer-relative Value factor, by 53 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, STOK or TARS?
STOK on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, STOK or TARS?
TARS on the Momentum factor, by 29 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, STOK or TARS?
TARS is the more resilient of the two, so the other name carries the higher downside risk. TARS carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is STOK more profitable than TARS?
The profitability evidence is mixed: gross margin 88.5% vs 93.2%; operating margin -9.1% vs -102%; ttm roe -20.9% vs -6.4%. STOK leads on one measure and TARS on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is TARS's lead over STOK getting stronger or weaker?
TARS lead: Weakening — the AIQ differential moved from 34 to 23 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the STOK vs TARS verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: STOK closes the Value gap — currently 53 points behind, the largest single contributor to TARS's edge; STOK's Death Cross Active resolves — a bearish trend rule currently active against it; TARS's conflicting signal state resolves bearish — it currently carries 5 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 11 points over 30 sessions, and a further 23-point move would eliminate TARS's advantage entirely.
What do the current signals say about STOK and TARS?
STOK: 3 bullish / 2 bearish / 2 neutral, conflicted. TARS: 5 bullish / 1 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on STOK is Death Cross Active (bearish, long horizon). On TARS it is Golden Cross Active (bullish, long horizon).
Compare STOK and TARS with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.